Company Profile
89bio, Inc. Stock Price, News & Analysis
Company overview
Business overview
89bio is a biopharmaceutical company focused on advancing a pipeline of therapeutic programs. Investors usually track how clinical data, regulatory milestones, and launch execution change the story over time.
Geographic Base and Sector Classification
Headquartered in the United States and listed on NASDAQ, 89bio is followed within the biotech universe for its exposure to catalyst-driven execution.
Business Model Characteristics
89bio follows a catalyst-driven model where the market watches how the company turns development work into repeatable value creation.
Position Within the Biotechnology Landscape
Compared with more mature healthcare peers, 89bio sits closer to the development side of the biotechnology landscape, where timing around data and approvals matters most.
Why the stock is moving
ETNB is trading with a steady catalyst profile while investors wait for the next headline that changes the story.
Future catalysts
89bio's catalysts are pegozafermin in MASH and severe hypertriglyceridemia, where the next data step can materially change the valuation. The company is still being judged on metabolic-disease execution.
Recent news
The five most recent feed items are shown below in reverse chronological order.
- 01
- 02
89bio Reports Second Quarter 2025 Financial Results and Corporate Updates
Source: 89bio, Inc.
- 03
89bio to Participate in Upcoming Investor Conferences
Source: 89bio, Inc.
- 04
89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Source: 89bio, Inc.
- 05
89bio, Inc. Announces Agreement to be Acquired by Roche
Source: 89bio, Inc.
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.